Peter Ordentlich
Fundador en SYNDAX PHARMACEUTICALS, INC. .
Fortuna: 5 451 $ al 30/04/2024
Cargos activos de Peter Ordentlich
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/11/2013 | - |
| Fundador | 11/10/2005 | - |
Historial de carrera de Peter Ordentlich
Antiguos cargos conocidos de Peter Ordentlich.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - | - |
| The Salk Institute for Biological Studies | Corporate Officer/Principal | - | - |
Formación de Peter Ordentlich.
| University of Pennsylvania | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Bolsa de valores
- Insiders
- Peter Ordentlich
- Experiencia
